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Impact of Autophagy Inhibition at Different Stages on Cytotoxic Effect of Autophagy Inducer in Glioblastoma Cells
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Introduction
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults [1, 2] . Despite of therapeutic advances, the median survival of GBM patients is only about 15 months after diagnosis [3, 4] . The most critical hallmark of most cancers is resistance to apoptosis, which can be converted by autophagy, another type of programmed cell death [5, 6] .
Autophagy is a lysosomal degradation process, which is associated with either cell survival or death [7] . Autophagy may allow tumors to survive under metabolic stress and lead to chemoresistance [8] . For this reason, autophagy inhibition can improve effect of of autophagy may result in cell death [10] . Several autophagy inducers exhibit anti-cancer function through persistent autophagy, such as the molecular target of rapamycin (mTOR) inhibitor rapamycin, phosphoinositide 3-kinase (PI3K) inhibitor LY294002, and arsenic trioxide (ATO) [11] [12] [13] [14] [15] [16] [17] [18] .
Interestingly, autophagy inhibitor and autophagy inducer, two kinds of contradictory drugs, sometimes produce synergistic effect on cancer therapy when used in combination [19, 20] . By far, numbers of basic studies and clinical trials evaluating such effect in cancer instance, autophagy inhibitor 3-methyladenine (3-MA) was found to decrease the toxicity A1 potentiate temozolomide cytotoxicity and induce apoptosis [21] . Since autophagy, as a multi-step process, can be inhibited at different stages, we hypothesized that inhibition of autophagy at different stages might play different roles in cytotoxic effect of autophagy inducers.
To test this hypothesis, in this study, we inhibited autophagy at different stages by pharmacological inhibitor or genetic ablation in GBM cells. To the best of our knowledge, the necessity of distinguishing between early and late stages of autophagy inhibition thus far has not been elucidated in GBM therapy. Our results indicated that inhibition of autophagy at late stage, not initial stage, increased the cytotoxic effect of autophagy inducers, providing a new approach for therapy of GBM.
Western blot analysis
Total protein were extracted from cultured cells. The cells were lysed in RIPA buffer with protease inhibitor. The lysates were separated by 10-15% SDS-PAGE gels, and then transferred to PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked in 5% skim milk with tween for 1h and incubated with primary antibodies overnight at 4 secondary antibodies (1:5000, Invitrogen, USA). Immunoreactive complexes were visualized using BeyoECL Plus (Beyotime, China). To perform western blot analysis, the following antibodies were used: rabbit LC3B antibody (1:1000; Sigma, USA), rabbit Beclin 1 antibody (1:500; Santa Cruz, CA, USA), rabbit SQSTM1 antibody (1:1000; Santa Cruz, CA, USA), rabbit caspase-3 antibody (1:1000; Cell Signaling Technology, USA), rabbit Rab7a antibody (1:250, Sigma, USA), mouse -actin antibody (1:2000; Santa Cruz, CA, USA).
Transmission electron microscopy
with 2.5% glutaraldehyde in phosphate buffer and preserved at 4 for further processing. Subsequently, ethanol and acetone. Cells were then embedded in araldite, and ultrathin section were obtained (50-60 nm), placed on uncoated copper grids, and stained with 3% lead citrate-uranyl acetate. The sections were examined with a transmission electron microscope (TEM; Hitachi, H-7650, Tokyo, Japan). 
Statistical analysis
The data from triplicate experiments were expressed as the mean ± SD. Statistical analysis between groups was performed using two-tailed Student's t test (GraphPad Prism version 5.0), where P < 0.05 P < 0.01 was strongly P asterisks).
Results

ATO reduced GBM cell viability and induced autophagy
To examine the cytotoxic effect of ATO on GBM cell lines, we treated two GBM cell lines (U87 and U251) with ATO at concentrations ranging from 1 M to 10 M for 24 h and 48 h. As shown in Fig. 1A , ATO inhibited cell viability in both cell lines in a dose-dependent we investigated whether ATO can trigger autophagy by examining autophagic vacuoles (AVs) substrate). Beclin 1, a key regulator of entry into autophagy, was also examined to assess autophagy. After exposing GBM cells to 3 M ATO for 12 h, the ultrastructure was analyzed by TEM. As shown in Fig. 1B , numerous vesicles with double membranes characteristic of autophagosome were observed in ATO group, while untreated cells showed few vesicles.
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Furthermore, western blot analysis using LC3 and SQSTM1 antibodies revealed that ATO induced autophagy in a dose-dependent manner. However, Beclin 1 level in the same lysates initiates autophagy via its interaction with class III PI3K, other than elevating its protein level [7] . Cysteine protease inhibitor E-64d and aspartic protease inhibitor pepstatin A can inhibit that ATO increased LC3-II level in a time-dependent manner. Note that the amount of LC3-II (Fig. 1D ). Together, these data indicated that ATO decreased GBM cell viability, accompanied with the activation of autophagy.
3-MA inhibited autophagy induced by ATO and reversed the cytotoxic effect of ATO in GBM
To determine whether the cell death was induced by autophagy, 3-MA was used to inhibit autophagy. 3-MA can block an early stage of autophagy by inhibiting the class III PI3K [20, 27, 28] . As shown in Fig. 2A , 1 mM 3-MA was able to reduce cell viability in both GBM M ATO with 1mM 3-MA exhibited Values represent Mean ± SD of three independent experiments. *P < .05; **P < .01; ***P < .001 compared with controls. (B) TEM photomicrographs of U87 and U251 cells. U87 and U251 cells were treated with cell culture media (negative control) or ATO (3 M) for 12 h. High -micrographs were displayed. Arrows indicate autophagic vacuoles (AVs). N, nucleus; M, mitochondrion; E, endoplasm reticulum. Scale bars represent 2 m. (C) Total cell lysates of U87 and U251 cells were extracted after incubation with indicated concentrations ( M) of ATO for 12 hours. Cell lysates were blotted with anti-LC3, anti-Beclin 1 and anti-SQSTM1 antibodies; anti--actin antibody was used as loading control. (D) Total cell lysates of U87 and U251 cells were extracted after incubation with 3 M ATO for 0 h, 4h, or 12h in the presence or absence of E-64d (10 g/ml) and pepstatin A (10 g/ml). Cell lysates were blotted with anti-LC3; anti--actin protein antibody was used as loading control.
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Cellular Physiology and Biochemistry little cytotoxic effect (Fig. 2B) . Results of TEM and western blots also indicated that 3-MA inhibited the autophagy level induced by ATO, as both number of AVs and level of LC3-II decreased ( Fig. 2C and D) . Together, these data demonstrated that 3-MA inhibited autophagy and cytotoxicity induced by ATO, suggesting that ATO inhibits cell growth via autophagy.
CQ impaired the clearance of autophagic vacuoles and sensitized GBM cells to ATO treatment
To further investigate the role autophagy played in cell death caused by ATO, another autophagy inhibitor CQ was studied in GBM cell lines. CQ can arrest the latter step of autophagy, fusion and degradation of autolysosome [29] . The results of MTT assay showed that GBM cells were sensitive to single treatment with CQ, but not with 5 M CQ (Fig. 3A) . However, combination of 3 M ATO and 5 M CQ produced dramatically higher inhibition rates compared with single-agent treatment (Fig.3B) . Unlike 3-MA, combination treatment Fig. 3C and D ). In addition, SQSTM1 level was higher in ATO+CQ group compared with control, suggesting that the cell death was associated with apoptosis. Caspase 3 cleavage is a central hallmark of apoptosis. After treated with indicated concentration of ATO, the level of cleaved caspase 3 increased in a dose-dependent manner (Fig. 3E) . Moreover, ATO + CQ combination resulted in higher level of cleaved caspase 3 compared either treatment alone, indicating that the cell lines treated with ATO ( Fig. 4B and C) . These data indicate that blockade of autophagy at initial stage decreases cytotoxicity of ATO. Notably, Beclin 1 knockdown prevented the synergistic cell death induced by ATO + CQ combination, suggesting that Beclin 1 is required for the synergistic effect of combination treatment (Fig. 4D) . The level of LC3-II and cleaved scrambled shRNA groups, suggesting that both autophagy and apoptosis induced by ATO and that Beclin 1 depletion could decrease apoptosis induced by ATO + CQ combination ( Fig. 4F  and G) . Collectively, these data demonstrated that the synergistic effect of ATO and CQ was mediated by autophagy and apoptosis in a Beclin 1-dependent manner. Since CQ inhibits autophagy at late stage, we hypothesized that autophagy blockade at late stage might enhance the cytotoxic effect of ATO. To test this, we knocked down the 
Discussion
autophagy begins with the formation of isolation membrane, a process regulated by class III PI3K-Beclin 1 complex. Then the membrane elongates and subsequently encloses to form the autophagosome, a double membrane structure. Following autophagosome formation, its outer membrane fuses with lysosomes to form autolysosomes, a single membrane structure. This process requires a number of regulators, such as Rab7 [7] . Ultimately, the lysosomal hydrolases degrade the autophagosome contents [7] . In this study, we demonstrate that 3-MA or Beclin 1 knockdown inhibits the initial step of autophagy induced by autophagy knockdown inhibits autophagosome-lysosome fusion and degradation steps, leading to accumulation of degradative AVs and enhanced apoptotic cell death. Given the auxiliary role of autophagy inhibitor may vary greatly at different stages, a distinction should be made between early stage and late stage of autophagy. Our results indicated that the effect of autophagy inhibitor and autophagy inducer combination involved both autophagy and apoptosis. The relationship between autophagy and apoptosis in cancers is complex. Autophagy and apoptosis regulate each other mostly in an inhibitory manner [12, 20, 34, 35] . However, sometimes autophagy may favour the induction of apoptosis. Apoptosis may begin with autophagy and autophagy can often end with apoptosis [36] . For instance, autophagosome formation generates a platform of activation of caspase 3 [37] . In addition, accumulation of autophagosomes may be toxic and trigger apoptosis, which is associated with increased ROS (reactive oxygen species) and subsequent mitochondrial permeabilization [38] . Thus, we speculated that autophagy inhibition and autophagy inducer combination induced apoptosis mostly through was always accompanied by accumulation of degradative AVs. Supporting this, a previous research showed that CQ-induced AV accumulation induced GBM cells to undergo apoptosis [39] . However, the underlying mechanism is still need to be further studied.
Our data have shown that Rab7 knockdown sensitized GBM cells to ATO treatment and induced stronger apoptosis. Thus far about 10 known Rab proteins are found to regulate addition, many Rab members, including Rab7, play important roles in invasiveness and metastasis in cancers [32, 41] . Furthermore, Rab7 was overexpressed in many cancers, including GBM, based on gene-centric robust multiarray analysis data [32] . These data support Rab7 as a promising target, especially when combined with autophagy inducers.
Our results demonstrated that CQ increased cytotoxicity of autophagy inducers in a Beclin-1 dependent manner, suggesting that autophagy plays a crucial role in such synergistic effects. However, Maycotte et al. reported that CQ sensitized autophagy inducers this inconsistency is that the molecule we targeted for inhibition of autophagy is Beclin 1, whereas their target is Atg12, a downstream of Beclin 1. Therefore, our method may inhibit autophagy more completely. In this study, we only used TEM and measurement of LC3-II with GFP-Cherry-LC3 construct, which was specially designed for monitoring autophagic multiple assays [27] .
In conclusion, our data indicated that inhibition of late steps of autophagy enhanced cytotoxicity of autophagy inducing drugs. Therefore, administration of such combination may act as a new approach to the treatment of GBM after further testing via in vivo experiments and clinical trials.
